SIX new medicines have been approved for use in NHS Scotland for illnesses including bladder cancer, a blood disorder, and arthritis.
The treatments were given the green light by the Scottish Medicines Consortium (SMC) to improve outcomes for patients suffering with hard-to-treat disorders where other drugs have failed.
They include the drug Avelumab, for an aggressive kind of bladder cancer called urothelial carcinoma, which may increase overall survival, delay cancerous growth, and prevent symptoms for longer, said the SMC.
Also accepted was Nivolumab, for oesophageal cancer affecting the gullet or food pipe, after the patient has had chemotherapy.
Patients with this debilitating condition have trouble swallowing and experience vomiting and pain with symptoms “often progressing very rapidly over just a few months” and it currently has “very limited” treatment options, said the SMC.
Elsewhere, one treatment for a type of white blood cell cancer was given interim approval for use “subject to ongoing evaluation and future reassessment”.
Tecartus is a type of CAR-T cell therapy that uses someone’s own immune cells, known as T-cells, to destroy cancerous ones.
It works by extracting them, then modifying them in the lab and then injecting them back into the patient, said the SMC.
It can be used to treat advanced mantle cell lymphoma when the cancer returns after two or more previous treatments.
“This treatment may provide the opportunity for a prolonged remission where the patient is able to participate in family and social activities,” said the SMC.
The medicine Avatrombopag was also accepted for sufferers of chronic immune thrombocytopenia who have not responded to previous treatment.
This is a long-term blood disorder in which the immune system destroys healthy platelets in the blood, which are needed to form clots and stop bleeding.
It offers a new treatment option “that may raise platelet levels for some patients who cannot use or who have not responded to current treatment options”, said the SMC.
Meanwhile, the drug Guselkumab was given the go-ahead for treating psoriatic arthritis, an inflammatory arthritis associated with the skin condition psoriasis.
Patients can suffer with pain, swollen joints, itchy skin and fatigue as well as other mobility issues.
Finally, Inclisiran was accepted for lowering cholesterol levels in patients at high cardiovascular risk on whom standard drug therapy has not been effective.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here